Accede al análisis completo con tu suscripción
Últimos 20 reportes · 10-K · 10-K/A · 10-Q · 8-K · Fuente: SEC EDGAR
Accede al análisis completo con tu suscripción
SEC CIK: 0000818686
We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future. We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets. Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. Our Business Segments We operate our business through three segments: United States, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and over-the-counter (“OTC”) products, as well as innovative medicines.
Ver másConsenso de Analistas
Precio Objetivo — 12 meses
$42.00
Mínimo
-0.2%
$47.50
Mediana
+12.9%
$47.58
Promedio
+13.0%
$55.00
Máximo
+30.7%
| Métrica | LTM jun 26 | 2025 | 2024 | 2023 | 🔒Premium | 🔒Premium | 🔒Premium | 🔒Premium | 🔒Premium | 🔒Premium | 🔒Premium | 🔒Premium |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INGRESOS Y MÁRGENES | ||||||||||||
| Ingresos Totales | 17.315B | 17.258B | 16.544B | 15.846B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Cost of Revenue | 8.232B | 8.320B | 8.481B | 8.200B | 🔒 | |||||||
| GASTOS OPERATIVOS | ||||||||||||
| SG&A | 1.305B | 1.287B | 1.161B | 1.162B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Amortización Intangibles | 565.000M | 581.000M | 588.000M | 616.000M | 🔒 | |||||||
| STOCK-BASED COMPENSATION | ||||||||||||
| Stock-Based Compensation | 168.000M | 157.000M | 123.000M | 121.000M | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| SBC / Revenue | 1.0% | 0.9% | 0.7% | 0.8% | 🔒 | |||||||
| RESULTADO NETO | ||||||||||||
| Pretax Income | 708.000M | 1.223B | -1.284B | -624.000M | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Interest Expense (P&L) | 916.000M | 916.000M | 1.002B | 1.029B | 🔒 | |||||||
| INVENTARIO Y LEASE | ||||||||||||
| Inventario Neto | 3.221B | 3.179B | 3.007B | 4.021B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| LIQUIDEZ | ||||||||||||
| Cash & Equivalentes | 3.655B | 3.556B | 3.300B | 3.226B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Total Liquid Assets | 3.655B | 3.556B | 3.300B | 3.226B | 🔒 | |||||||
| BALANCE — ACTIVOS | ||||||||||||
| PP&E Neto | 3.928B | 4.080B | 4.581B | 5.750B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Goodwill | 15.839B | 16.000B | 15.147B | 17.177B | 🔒 | |||||||
| CAPITAL Y DEUDA | ||||||||||||
| Patrimonio Neto | 7.753B | 7.910B | 5.373B | 7.506B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Invested Capital | 7.753B | 6.641B | 6.439B | 7.655B | 🔒 | |||||||
| FLUJO DE CAJA Y CAPEX | ||||||||||||
| Cash Flow Operativo (CFO) | 1.898B | 1.649B | 1.247B | 1.368B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Capex | 551.000M | 501.000M | 498.000M | 526.000M | 🔒 | |||||||
| RATIOS | ||||||||||||
| ROIC (NOPAT / IC) | 20.3% | 32.5% | — | — | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Gross Margin | 52.5% | 51.8% | 48.7% | 48.3% | 🔒 | |||||||
Cifras en miles de millones (B) · Fuente: SEC/EDGAR
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Gross Profit | 9.083B | 8.938B | 8.064B | 7.645B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Gross Margin | 52.5% | 51.8% | 48.7% | 48.3% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Amort. Intang / Revenue | 3.3% | 3.4% | 3.5% | 3.9% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Operating Income | 1.603B | 2.157B | -303.000M | 433.000M | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Operating Margin | 9.3% | 12.5% | -1.8% | 2.7% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Tax Expense | 12.000M | -180.000M | 676.000M | -7.000M | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Beneficio Neto | 706.000M | 1.410B | -1.639B | -559.000M | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Margen Neto | 4.1% | 8.2% | -9.9% | -3.5% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| EPS Diluido | 0.60 | 1.21 | -1.45 | -0.50 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| EPS Básico | 0.62 | 1.23 | -1.45 | -0.50 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Intangibles | 3.447B | 3.781B | 4.418B | 5.387B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Activo Total | 39.857B | 40.748B | 39.326B | 43.479B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Pasivo Total | 32.100B | 32.834B | 33.606B | 35.353B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Acciones en Circulación | 1.165B | 1.163B | 1.131B | 1.119B | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Free Cash Flow (FCF) | 1.347B | 1.148B | 749.000M | 842.000M | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| FCF Margin | 7.8% | 6.7% | 4.5% | 5.3% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| NOPAT | 1.576B | 2.157B | — | — | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Adquisiciones (Business) | 0.00 | 0.00 | 15.000M | 0.00 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| 🔒 |
| Operating Margin | 9.3% | 12.5% | -1.8% | 2.7% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Amort. Intang / Revenue | 3.3% | 3.4% | 3.5% | 3.9% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| FCF Margin | 7.8% | 6.7% | 4.5% | 5.3% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| ROE (avg equity) | 9.0% | 21.2% | -25.4% | -7.3% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| ROA (avg assets) | 1.8% | 3.5% | -4.0% | -1.3% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
| Margen Neto | 4.1% | 8.2% | -9.9% | -3.5% | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 | 🔒 |
Precio actual · USD
$41.08
P/E LTM
68.47
ROIC (NOPAT / IC)
20.3%
Gross Margin
52.5%
Operating Margin
9.3%
Amort. Intang / Revenue
3.3%
FCF Margin
7.8%
ROE (avg equity)
9.0%
ROA (avg assets)
1.8%